A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Recruiting now
Conditions studied: Plaque Psoriasis
In brief
The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the individual rationales for switching biologics.
Key facts
- Study ID
- NCT06030076
- Run by
- Almirall, S.A.
- People needed
- 50
- Starts
- 2023-09-06
- Expected to finish
- 2025-10-01
- Last updated by the study team
- 2025-01-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Written informed consent.
- >=18 years of age.
- Moderate-to-severe plaque psoriasis currently treated with a biologic therapy (TNFα antagonist, IL12/23 antagonist, IL17 antagonist).
- Switch to tildrakizumab due to:
- primary or secondary treatment failure (PASI >= 3 or ΔPASI < 75 and/or DLQI > 5)
- adverse events, contraindication, intolerance
- patient wish (dosing regimen), lack of adherence, or other, including nonmedical reason
- Treatment with tildrakizumab planned in the frame of clinical practice.
You may not qualify if…
- Patient appears to be unwilling or unable to comply with the requirements of the study or who, in the opinion of the Investigator, should not participate in the study.
- >=3 previous biologic treatments in the last 3 years.
- Participation in a clinical trial simultaneous to participation in SW-ATCH.
- Any condition preventing prescription of Tildrakizumab according to the SmPC, including but not restricted to any contraindication or history of hypersensitivity or intolerance.
- Patient dependent on the Investigator.
- Previous treatment with Tildrakizumab.
Where it is running
- Gesundheitszentrum Citypark Graz — Graz, Styria, Austria (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.